By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Exiqon today announced it has granted a non-exclusive license for its locked nucleic acids technology to Becton Dickinson for the development of diagnostics for infectious diseases.

Under the terms of the deal, Exiqon will receive upfront and milestone payments and royalties on global sales of products stemming from the agreement. No other financial terms were disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.